• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec8
Syndax Pharmaceuticals Announces Positive Trial Results for Revuforj® in AML at ASH Annual Meeting
11:50
Nov24
Barclays Maintains Overweight Rating and Raises Target Price for Syndax Pharmaceuticals
18:57
Nov14
H.C. Wainwright and J.P. Morgan Reiterate Buy Rating on Syndax Pharmaceuticals
11:42
Nov4
Syndax Pharmaceuticals Reports Exceeding EPS Expectations for Q3, Stock Price Rises
17:23
Lawson Reiterates Buy Rating on Syndax Pharmaceuticals
07:56
Syndax Pharma released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 58 M and EPS of USD -1.8167
00:00

Schedules & Filings

Schedules
Filings
Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 45.87 M, Net Income -60.72 M, EPS -0.7009

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 37.96 M, Net Income -71.85 M, EPS -0.8321

May5
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 20.04 M, Net Income -84.85 M, EPS -0.9846

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
BBGI
16.690
+312.10%
+12.640
SRV.RT
0.0900
+111.76%
+0.048
BEAT
1.550
+92.43%
+0.745
ENVB
10.330
+74.49%
+4.410
BDRX
6.720
+65.11%
+2.650
ASPC
16.810
+60.40%
+6.330
IRBT
5.240
+48.44%
+1.710
CGTL
0.9727
+47.40%
+0.313
MIGI
6.700
+45.65%
+2.100
PLAB
37.350
+45.39%
+11.660
View More